EP
XERS icon

Essential Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Essential Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.24K Sell
1,167
-121
-9% -$773 ﹤0.01% 1249
2026
Q1 		$7.47K Hold
1,288
– – ﹤0.01% 1388
2025
Q4 		$10.1K Sell
1,288
-139
-10% -$1.09K ﹤0.01% 1166
2025
Q3 		$11.6K Buy
1,427
+362
+34% +$2.4K ﹤0.01% 1109
2025
Q2 		$4.97K Buy
+1,065
New +$4.88K ﹤0.01% 1057

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Essential Partners's XERS Position: Q2 2026 in Review

Essential Partners reduced its Xeris Biopharma Holdings (XERS) stake by 9.4% in Q2 2026, selling an estimated $773 and leaving 1,167 shares worth $9.24K. The position accounts for ﹤0.01% of the portfolio, ranked #1249.

Essential Partners first reported a position in XERS in Q2 2025 and has held it in 5 quarters since. The position peaked at $11.6K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Essential Partners held 1,167 shares of Xeris Biopharma Holdings worth $9.24K as of Q2 2026.
  • Essential Partners sold 121 Xeris Biopharma Holdings shares in Q2 2026, an estimated $773.
  • Xeris Biopharma Holdings made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1249 holding.
  • Essential Partners first reported a position in Xeris Biopharma Holdings in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Xeris Biopharma Holdings position peaked at $11.6K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.